Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on October 1, 2006

Papers In Press, published online ahead of print July 27, 2006
J. Lipid Res., doi:10.1194/jlr.D600024-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
D600024-JLR200v1
47/10/2346    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Werkhoven, M. A.
Right arrow Articles by Pitt, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Werkhoven, M. A.
Right arrow Articles by Pitt, J. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on June 7, 2006
Revised on July 26, 2006
Accepted on July 27, 2006

Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth syndrome

Michiel Adriaan van Werkhoven, David Ross Thorburn, Agi Kyra Gedeon, and James Jonathon Pitt

Metabolic Lab., Genetic Health Services Victoria, Melbourne, VIC 3052

Corresponding Author: james.pitt{at}ghsv.org.au

Barth Syndrome (BTHS) is an X-linked recessive disorder that results in abnormal metabolism of the mitochondrial phosholipid cardiolipin (CL). Cardiolipins are decreased and monolysocardiolipins (MLCLs), intermediates in CL metabolism, are increased in a variety of tissues. Measurement of decreased CL levels in skin fibroblasts has previously been proposed as a diagnostic test for BTHS. We investigated whether elevated MLCL is specific for BTHS and if the MLCL over CL ratio is a more sensitive and specific marker for BTHS. We measured CLs and MLCLs in skin fibroblasts from 5 BTHS patients, 8 controls and 14 patients with similar biochemical and clinical findings as BTHS (group D), using high performance liquid chromatography-mass spectrometry. Our results showed a clear decrease of CL in combination with a marked increase of MLCL in fibroblasts from BTHS patients when compared to controls. MLCL/CL ratios ranged from 0.03-0.12 in control fibroblasts and from 5.41-13.83 in BTHS fibroblasts. In group D, the MLCL/CL ratio range was 0.02-0.06. We therefore conclude that elevations of MLCLs are specific for BTHS and the MLCL/CL ratio in fibroblasts is a better diagnostic marker than CL alone. We also report the finding of 2 novel mutations in the TAZ gene causing BTHS.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
W. Kulik, H. van Lenthe, F. S. Stet, R. H. Houtkooper, H. Kemp, J. E. Stone, C. G. Steward, R. J. Wanders, and F. M. Vaz
Bloodspot Assay Using HPLC-Tandem Mass Spectrometry for Detection of Barth Syndrome
Clin. Chem., February 1, 2008; 54(2): 371 - 378.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement